Novel therapeutic opportunities of kisspeptin
Open Access
- 1 September 2024
- journal article
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 11 (4) , 324-333
Abstract
Diseases associated with disorders of sexual development, the reproductive system, delayed of puberty onset are of high relevance. This negatively affect the health of young people, the demographic indicators, fertility and require a search for therapy. This review presents current data on the role of the kisspeptin ligand-receptor system KISS/KISS1R, the discovery of which was of revolutionary significance for deciphering the genesis of neuroendocrine regulation of the reproductive system.A review and analysis of clinical and experimental research from recent decades, aimed at studying kisspeptin and its agonists as a potential therapeutic approach. Data are presented on the positive effect of kisspeptin on the pulse secretion of GnRH and gonadotropins, which can be used in the treatment of hypogonadotropic hypogonadism, ovulation disorders and other diseases of the reproductive system. Outside the human hypothalamus, kisspeptin and its receptor are expressed in the brain in key limbic and paralimbic regions, and in peripheral tissues. We summarise data on the pharmacological use of kisspeptin in reproductive disorders and fertility treatment, as well as its putative utility in hypoactive sexual desire disorder, osteoporosis and non-alcoholic fatty liver disease, now known as metabolic dysfunction-associated fatty liver disease.Keywords
This publication has 43 references indexed in Scilit:
- Novel therapeutic avenues for kisspeptinCurrent Opinion in Pharmacology, 2022
- Clinical Potential of Kisspeptin in Reproductive HealthTrends in Molecular Medicine, 2021
- Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatmentClinical Endocrinology, 2018
- A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trialHuman Reproduction, 2017
- Pubertal development and regulationThe Lancet Diabetes & Endocrinology, 2016
- Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolideEuropean Journal of Pharmacology, 2014
- Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: Kisspeptin‐10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadismClinical Endocrinology, 2013
- A single injection of kisspeptin‐54 temporarily increases luteinizing hormone pulsatility in healthy womenClinical Endocrinology, 2013
- Twice-Weekly Administration of Kisspeptin-54 for 8 Weeks Stimulates Release of Reproductive Hormones in Women With Hypothalamic AmenorrheaClinical Pharmacology & Therapeutics, 2010
- Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54Proceedings of the National Academy of Sciences, 2003